Am J Psychiatry 155:1512-1520, November 1998
©Copyright 1998 American Psychiatric Association
A Randomized, Placebo-Controlled Dose-Comparison Trial of Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer's Disease
D.P. Devanand, M.D.,
Karen Marder, M.D., M.P.H.,
Kristin S. Michaels, M.A.,
Harold A. Sackeim, Ph.D.,
Karen Bell, M.D.,
Maria A. Sullivan, M.D., Ph.D.,
Thomas B. Cooper, M.A.,
Gregory H. Pelton, M.D., and
Richard Mayeux, M.D., M.Sc.
Objective:The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.Method:In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2–3 mg/day (standard dose), and haloperidol, 0.50–0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease. For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.Results:For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation. Response rates according to three sets of criteria were greater with the standard dose (55%–60%) than the low dose (25%–35%) and placebo (25%–30%). The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs. Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects. Conclusions:The results indicated a favorable therapeutic profile for haloperidol in doses of 2–3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs. A starting dose of 1 mg/day with gradual, upward dose titration is recommended. The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors. Am J Psychiatry 1998; 155: 1512-1520
This article has been cited by other articles:
|
|
|
|
 
H. C. Kales, M. Valenstein, H. M. Kim, J. F. McCarthy, D. Ganoczy, F. Cunningham, and F. C. Blow
Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications
Am J Psychiatry,
October 1, 2007;
164(10):
1568 - 1576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Blaszczyk and M. Mathys
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Journal of Pharmacy Practice,
February 1, 2007;
20(1):
13 - 28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. N. Tariot, L. Schneider, I. R. Katz, J. E. Mintzer, J. Street, M. Copenhaver, and C. Williams-Hughes
Quetiapine Treatment of Psychosis Associated With Dementia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Am J Geriatr Psychiatry,
September 1, 2006;
14(9):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Karim and E. J. Byrne
Treatment of psychosis in elderly people
Advan. Psychiatr. Treat.,
July 1, 2005;
11(4):
286 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Voyer, R. Verreault, P. N. Mengue, D. Laurin, L. Rochette, L. S. Martin, and L. Baillargeon
Determinants of Neuroleptic Drug Use in Long-Term Facilities for Elderly Persons
Journal of Applied Gerontology,
June 1, 2005;
24(3):
179 - 195.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings
Alzheimer's Disease
N. Engl. J. Med.,
July 1, 2004;
351(1):
56 - 67.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Focus,
April 1, 2004;
2(2):
268 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Moretti, P. Torre, R. M. Antonello, T. Cattaruzza, G. Cazzato, and A. Bava
Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study
American Journal of Alzheimer's Disease and Other Dementias,
March 1, 2004;
19(2):
81 - 88.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Hoeh, L. Gyulai, D. Weintraub, and J. Streim
Pharmacologic Management of Psychosis in the Elderly: A Critical Review
J Geriatr Psychiatry Neurol,
December 1, 2003;
16(4):
213 - 218.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. M. Bassiony and C. G. Lyketsos
Delusions and Hallucinations in Alzheimer's Disease: Review of the Brain Decade
Psychosomatics,
October 1, 2003;
44(5):
388 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A Schatz
Olanzapine for Psychotic and Behavioral Disturbances in Alzheimer Disease
Ann. Pharmacother.,
September 1, 2003;
37(9):
1321 - 1324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Boustani, B. Peterson, L. Hanson, R. Harris, and K. N. Lohr
Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med,
June 3, 2003;
138(11):
927 - 937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Pelton, D. P. Devanand, K. Bell, K. Marder, K. Marston, X. Liu, and T. B. Cooper
Usefulness of Plasma Haloperidol Levels for Monitoring Clinical Efficacy and Side Effects in Alzheimer Patients With Psychosis and Behavioral Dyscontrol
Am J Geriatr Psychiatry,
April 1, 2003;
11(2):
186 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Ramadan, B. J. Naughton, and R. Prior
Correlates of Behavioral Disturbances and Pattern of Psychotropic Medication Use in Five Skilled Nursing Facilities
J Geriatr Psychiatry Neurol,
March 1, 2003;
16(1):
8 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. LAWLOR
Managing behavioural and psychological symptoms in dementia
The British Journal of Psychiatry,
December 1, 2002;
181(6):
463 - 465.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Psychiatr Serv,
November 1, 2002;
53(11):
1419 - 1431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study
JAMA,
September 25, 2002;
288(12):
1475 - 1483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Breitbart, A. Tremblay, and C. Gibson
An Open Trial of Olanzapine for the Treatment of Delirium in Hospitalized Cancer Patients
Psychosomatics,
June 1, 2002;
43(3):
175 - 182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Scarmeas, J. Brandt, M. Albert, D. P. Devanand, K. Marder, K. Bell, A. Ciappa, B. Tycko, and Y. Stern
Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease
Neurology,
April 23, 2002;
58(8):
1182 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Schneider, P. N. Tariot, C. G. Lyketsos, K. S. Dagerman, K. L. Davis, S. Davis, J. K. Hsiao, D. V. Jeste, I. R. Katz, J. T. Olin, et al.
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology
Am J Geriatr Psychiatry,
November 1, 2001;
9(4):
346 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al.
Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology,
May 8, 2001;
56(9):
1154 - 1166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Herrmann and S. E. Black
Behavioral disturbances in dementia: Will the real treatment please stand up?
Neurology,
November 14, 2000;
55(9):
1247 - 1248.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teri, R. G. Logsdon, E. Peskind, M. Raskind, M. F. Weiner, R. E. Tractenberg, N. L. Foster, L. S. Schneider, M. Sano, P. Whitehouse, et al.
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Neurology,
November 14, 2000;
55(9):
1271 - 1278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Street, W. S. Clark, K. S. Gannon, J. L. Cummings, F. P. Bymaster, R. N. Tamura, S. J. Mitan, D. L. Kadam, T. M. Sanger, P. D. Feldman, et al.
Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial
Arch Gen Psychiatry,
October 1, 2000;
57(10):
968 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mayeux and M. Sano
Treatment of Alzheimer's Disease
N. Engl. J. Med.,
November 25, 1999;
341(22):
1670 - 1679.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Knable
Haloperidol, 2-3 mg/day, decreased psychosis and disruptive behaviours in Alzheimer's disease
Evid. Based Ment. Health,
May 1, 1999;
2(2):
48 - 48.
[Full Text]
|
|
|
|
|
|
|
Haloperidol for Psychotic or Disruptive Alzheimer's Patients
Journal Watch Psychiatry,
January 1, 1999;
1999(101):
19 - 19.
[Full Text]
|
|
|
|
|
|
|
Dementia and Disruptive Behavior in Alzheimer's Disease
Journal Watch Women's Health,
December 1, 1998;
1998(1201):
19 - 19.
[Full Text]
|
|
|
|
|
|
|
Haloperidol for Psychotic or Disruptive Alzheimer's Patients
Journal Watch (General),
November 17, 1998;
1998(1117):
2 - 2.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
